Mallinckrodt Pharmaceuticals to Hold Investor Briefing in New York
DUBLIN--(BUSINESS WIRE)--Nov. 8, 2013--
(NYSE:MNK), a global specialty pharmaceutical and global medical imaging
company, will hold an investor briefing on November 14, 2013. The
meeting will be held at the Grand Hyatt at 109 East 42nd Street at Grand
Central Terminal New York, NY from 8:30am to 9am Eastern Standard Time.
Mark Trudeau, President and CEO of Mallinckrodt, along with members of
Mallinckrodt’s senior management team, will present.
Individuals who are unable to attend the meeting in person will be able
to view a live video and webcast at Mallinckrodt’s website: http://mallinckrodt.com/investor_relations.aspx
or participate by telephone: 877-348-9353 in the U.S – and 253-237-1159
outside the U.S. The access code for all callers is 93659517. A replay
of the presentation and the presentation materials will be available at
the same website following the conclusion of the meeting.
Mallinckrodt is a global specialty pharmaceuticals business that
develops, manufactures, markets and distributes specialty pharmaceutical
products and medical imaging agents. The company’s Specialty
Pharmaceuticals segment includes branded and generic drugs, and the
Global Medical Imaging segment includes contrast media and nuclear
imaging agents. Mallinckrodt has approximately 5,500 employees worldwide
with direct sales in roughly 70 countries. To learn more about
Mallinckrodt, visit www.mallinckrodt.com.
John Moten, 314-654-6650
Vice President, Investor
Manager, Media Relations
Senior Vice President, Communications